Cytyc, headquartered in Massachusetts, was founded in 1987 by Stanley Lapidus, and has become pre-eminent in the women#8217;s health industry. Its products cover a range of women#8217;s health applications, including cervical cancer screening, treatment of excessive menstrual bleeding, radiation treatment of early-stage breast cancer and breast cancer risk assessment. The company#8217;s domestic diagnostics segment developed and markets the ThinPrep#174; Pap test in the US. However, in the face of growing competition from TriPath Imaging#8217;s cheaper liquid-based Pap test, and in order to expand its product portfolio, Cytyc has recently acquired two companies: Adeza Biomedical and Adiana. This article discusses Cytyc#8217;s development of the breakthrough ThinPrep test, and its diversification through acquisition strategy, with particular emphasis of the two most recent acquisitions.